PMID- 21593770
OWN - NLM
STAT- MEDLINE
DCOM- 20111003
LR  - 20131121
IS  - 1523-1747 (Electronic)
IS  - 0022-202X (Linking)
VI  - 131
IP  - 8
DP  - 2011 Aug
TI  - Antimicrobial and anti-inflammatory effects of Cecropin A(1-8)-Magainin2(1-12) 
      hybrid peptide analog p5 against Malassezia furfur infection in human 
      keratinocytes.
PG  - 1677-83
LID - 10.1038/jid.2011.112 [doi]
AB  - The lipophilic fungus Malassezia furfur (M. furfur) is a commensal microbe 
      associated with several chronic diseases such as pityriasis versicolor, 
      folliculitis, and seborrheic dermatitis. Because M. furfur-related diseases are 
      difficult to treat and require prolonged use of medications, the treatment for M. 
      furfur-related skin diseases is supposed to gain control over M. furfur growth 
      and the inflammation associated with it, as well as to prevent secondary 
      infections. In this study, we investigated the antifungal and anti-inflammatory 
      effects of cecropin A(1-8)-magainin 2(1-12) hybrid peptide analog P5 on M. 
      furfur. The minimal inhibitory concentration of P5 against M. furfur was 0.39 muM, 
      making it 3-4 times more potent than commonly used antifungal agents such as 
      ketoconazole (1.5 muM) or itraconazole (1.14 muM). P5 efficiently inhibited the 
      expression of IL-8 and Toll-like receptor 2 in M. furfur-infected human 
      keratinocytes without eukaryotic cytotoxicity at its fungicidal concentration. 
      Moreover, P5 significantly downregulated NF-kappaB activation and intracellular 
      calcium fluctuation, which are closely related with enhanced responses of 
      keratinocyte inflammation induced by M. furfur infection. Taken together, these 
      observations suggest P5 may be a potential therapeutic agent for M. 
      furfur-associated human skin diseases because of its distinct antifungal and 
      anti-inflammatory action.
FAU - Ryu, Sunhyo
AU  - Ryu S
AD  - Department of Dermatology, University of Arkansas for Medical Sciences, Little 
      Rock, Arkansas, USA.
FAU - Choi, Soon-Yong
AU  - Choi SY
FAU - Acharya, Samudra
AU  - Acharya S
FAU - Chun, Young-Jin
AU  - Chun YJ
FAU - Gurley, Catherine
AU  - Gurley C
FAU - Park, Yoonkyung
AU  - Park Y
FAU - Armstrong, Cheryl A
AU  - Armstrong CA
FAU - Song, Peter I
AU  - Song PI
FAU - Kim, Beom-Joon
AU  - Kim BJ
LA  - eng
PT  - Journal Article
DEP - 20110519
PL  - United States
TA  - J Invest Dermatol
JT  - The Journal of investigative dermatology
JID - 0426720
RN  - 0 (Antifungal Agents)
RN  - 0 (Antimicrobial Cationic Peptides)
RN  - 0 (Interleukin-8)
RN  - 0 (NF-kappa B)
RN  - 0 (cecropin A(1-8)magainin 2(1-12))
RN  - SY7Q814VUP (Calcium)
SB  - IM
MH  - Antifungal Agents/*pharmacology
MH  - Antimicrobial Cationic Peptides/*pharmacology
MH  - Calcium/metabolism
MH  - Calcium Signaling/drug effects/immunology
MH  - Cell Nucleus/immunology/metabolism
MH  - Cells, Cultured
MH  - Dermatomycoses/*drug therapy/immunology
MH  - Dose-Response Relationship, Drug
MH  - Humans
MH  - Interleukin-8/metabolism
MH  - Keratinocytes/cytology/immunology/*microbiology
MH  - Malassezia/*drug effects/immunology
MH  - Microbial Sensitivity Tests
MH  - NF-kappa B/metabolism
EDAT- 2011/05/20 06:00
MHDA- 2011/10/04 06:00
CRDT- 2011/05/20 06:00
PHST- 2011/05/20 06:00 [entrez]
PHST- 2011/05/20 06:00 [pubmed]
PHST- 2011/10/04 06:00 [medline]
AID - S0022-202X(15)35362-8 [pii]
AID - 10.1038/jid.2011.112 [doi]
PST - ppublish
SO  - J Invest Dermatol. 2011 Aug;131(8):1677-83. doi: 10.1038/jid.2011.112. Epub 2011 
      May 19.